Latest News and Press Releases

Transparency Notification from Shareholder Ghent, Belgium – 3 October 2025 – Sequana Medical NV (Euronext Brussels: SEQUA) (the "Company" or "Sequana Medical"), a pioneer in the treatment of...

Ghent, Belgium – September 30, 2025 – Sequana Medical NV (Euronext Brussels: SEQUA, the “Company” or “Sequana Medical”), a pioneer in the treatment of drug-resistant fluid overload in liver disease,...

SEQUANA MEDICAL ANNOUNCES NEW SHARE CAPITAL AMOUNT AND NEW NUMBER OF SHARES Ghent, Belgium, 26 September 2025 – Sequana Medical NV (Euronext Brussels: SEQUA) (the "Company" or "Sequana Medical"), a...

Sequana Medical announces H1 2025 results and provides business update alfapump® US commercialisation underway; Strengthened US reimbursement with CMS approval of NTAP “top-up” reimbursement; On...

SEQUANA MEDICAL ANNOUNCES THE ISSUANCE OF A SUBSCRIPTION REQUEST NOTICE UNDER THE SHARE SUBSCRIPTION FACILITY AGREEMENT WITH GEM Ghent, Belgium, 15 September 2025 – Sequana Medical NV (Euronext...

SEQUANA MEDICAL ANNOUNCES NEW SHARE CAPITAL AMOUNT AND NEW NUMBER OF SHARES Ghent, Belgium, 8 September 2025 – Sequana Medical NV (Euronext Brussels: SEQUA) (the "Company" or "Sequana Medical"), a...

Transparency Notification from Shareholders Ghent, Belgium – 14 August 2025 – Sequana Medical NV (Euronext Brussels: SEQUA) (the "Company" or "Sequana Medical"), a pioneer in the treatment of...

SEQUANA MEDICAL ANNOUNCES THE ISSUANCE OF A SUBSCRIPTION REQUEST NOTICE UNDER THE SHARE SUBSCRIPTION FACILITY AGREEMENT WITH GEM Ghent, Belgium, 7 August 2025 – Sequana Medical NV (Euronext Brussels:...

CMS Approves Additional Payment for Sequana Medical’s alfapump® system in Hospital Inpatient Cases alfapump® New Technology Add-on Payment (NTAP) Included in CMS Final Fiscal Year 2026 Rule and in...

Use of alfapump® to control ascites enabling elective umbilical hernia repair published in Hernia Untreated umbilical hernias occur in 20% of patients with ascites due to liver cirrhosis. Without...